Ultragenyx Pharma (RARE) PT Lowered to $45 at Citi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RARE Hot Sheet
Price: $16.10 -4.05%
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
13 Buy, 13 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
Citi analyst Yigal Nochomovitz lowered the price target on Ultragenyx Pharma (NASDAQ: RARE) to $45.00 (from $66.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Evercore ISI Downgrades Reddit (RDDT) to In Line, Removes From Tactical Outperform List
- John B. Sanfilippo & Son, Inc. (JBSS) PT Lowered to $79 at Freedom Broker
- Alnylam Pharmaceuticals (ALNY) PT Lowered to $350 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
